Clinical Trial

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Study acronym: SCLC
Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05271292
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Enrollment 36 participants
Start Date 2022-08-26
Primary Completion 2025-03 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-07-16